Express Scripts (ESRX) 69.65 $ESRX The Economist

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Express Scripts (ESRX) 69.65 $ESRX

The Economist Presents: "The War on Cancer: Scaling Progress"
PR Newswire - Thu Sep 15, 9:00AM CDT
The Economist Events will hold the second annual War on Cancer Forum, on the theme of "Scaling Progress" on September 28th 2016 at the Hyatt Regency Hotel in Boston.
ESRX: 69.65 (+0.40)

After Yesterday's Decline of 2.02%, Express Scripts Offers Investors Better Value
Comtex SmarTrend(R) - Tue Sep 13, 4:12PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $70.64 to a high of $71.51. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $70.72 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

Express Scripts Set to Possibly Rebound After Yesterday's Selloff of 2.02%
Comtex SmarTrend(R) - Tue Sep 13, 4:10PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $70.64 to a high of $71.51. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $70.72 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Express Scripts Holding Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Fri Sep 09, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / September 9, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Express Scripts Holding Company (NASDAQ: ESRX).
ANTM: 128.59 (+2.83), ESRX: 69.65 (+0.40)

Express Scripts Launches Inflammatory Conditions Care Value Program(SM), Making America's Costliest Medication Class More Affordable
PR Newswire - Thu Sep 08, 6:00AM CDT
Express Scripts (NASDAQ: ESRX) today launched its Inflammatory Conditions Care Value Programâ", a comprehensive approach to control costs and improve care for people with inflammatory conditions like rheumatoid arthritis, psoriasis and Crohn's Disease.
ESRX: 69.65 (+0.40)

Cost Effective Benefits Of New "First Step" Infertility Treatment Continue
BusinessWire - Wed Sep 07, 6:00AM CDT
Despite the recent findings that enrollment in the Affordable Care Act's (ACA) insurance exchanges has fallen, Conceivex said today that couples across the country continue to be able to take advantage of a new, insurance-covered "first step" therapy to overcome infertility.
ESRX: 69.65 (+0.40)

Express Scripts Holding Company to Present at an Upcoming Conference
PR Newswire - Thu Sep 01, 1:38PM CDT
Express Scripts Holding Company (Nasdaq: ESRX) (the "Company" or "Express Scripts" announced today that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 1:00 p.m. Eastern Time (12:00 p.m. Central Time).
ESRX: 69.65 (+0.40)

Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 69.65 (+0.40), ANIP: 65.12 (+0.28), LLY: 80.87 (+0.99)

Express Scripts Launches Diabetes Care Value Programâ", Guaranteeing More Affordable, Higher-Quality Diabetes Care
PR Newswire - Tue Aug 30, 11:01PM CDT
Express Scripts (NASDAQ: ESRX) today announced the launch of its Diabetes Care Value Programâ", the industry's most comprehensive approach to improve pharmacy care while controlling plan costs for people with diabetes.
ESRX: 69.65 (+0.40)

Blog Coverage Walgreens Boots Alliance Partners with Prime Therapeutics for a Bigger Slice of the Prescription Drug Market
ACCESSWIRE - Tue Aug 30, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 30, 2016 / Active Wall St. blog coverage looks at the headline from Walgreens Boots Alliance, Inc. (NASDAQ: WBA) announced a strategic partnership with pharmacy benefit manager (PBM) Prime Therapeutics on August 29, 2016 to form a new retail pharmacy network that combines mail order and speciality pharma business. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
ESRX: 69.65 (+0.40), WBA: 80.58 (-0.06), UNH: 139.91 (+2.44), RAD: 8.10 (+0.06)


Mylan launching cheaper, generic version of EpiPen
By LINDA A. JOHNSON and TOM MURPHY - AP - Mon Aug 29, 4:20PM CDT
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues — and looming competition threatens its near-monopoly.
ESRX: 69.65 (+0.40), MYL: 41.91 (+0.65)

Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 74.09 (-0.01), TSLA: 205.22 (+0.58), ENDP: 20.09 (-0.20), F: 12.09 (+0.09), MDT: 87.14 (+0.78), GME: 28.13 (+0.41), MYL: 41.91 (+0.65), PDCO: 46.80 (+0.57), TIF: 72.27 (+0.74), BA: 130.56 (+2.77), ESRX: 69.65 (+0.40), STJ: 79.44 (+0.55), SSYS: 22.22 (+0.23), TECD: 86.19 (+1.11), ADSK: 71.69 (+2.90)


Mylan boosts EpiPen patient programs, doesn't budge on price
By LINDA A. JOHNSON and TOM MURPHY - AP - Thu Aug 25, 4:45PM CDT
The maker of EpiPens offered patients more help to pay for its costly emergency allergy shots but didn't budge Thursday on the $608 price.
ESRX: 69.65 (+0.40), VRX: 26.97 (+0.64), MYL: 41.91 (+0.65), VRX.TO: 35.34 (+0.51)

Look for Shares of Express Scripts to Potentially Rebound after Yesterday's 4.00% Sell Off
Comtex SmarTrend(R) - Thu Aug 25, 11:59AM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $73.01 to a high of $76.08. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $76.00 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

SmarTrend Watching for Potential Rebound in Shares of Express Scripts After 4.00% Loss
Comtex SmarTrend(R) - Thu Aug 25, 11:57AM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $73.01 to a high of $76.08. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $76.00 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 69.65 (+0.40)

PharmCo to Offer Emergency Prescriptions to Residents in Louisiana Flood Zone
Marketwired - Thu Aug 25, 9:10AM CDT
MIAMI, FL--(Marketwired - August 25, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, has begun offering emergency prescription services to Louisiana Flood Zone residents.
ESRX: 69.65 (+0.40)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Clearwater Analytics Expands Leadership for APAC Growth and Awards

Updated Category News Views 392

Clearwater Analytics Strengthens APAC Leadership Clearwater Analytics (NYSE: CWAN) is making significant strides in the Asia-Pacific region with new leadership appointments and notable award recognitions. Recently, the company appointed George Hindmarsh as the Head of Sales and Business Development for the APAC region. This key move is expected to play a crucial role in...

Continue Reading
David Totaro Brings Expertise to Liberty Partners Group

Updated Category News Views 128

Exciting New Addition to Liberty Partners Group Liberty Partners Group is thrilled to announce the entry of David Totaro to its prestigious team. With a wealth of experience in government relations and public affairs, David will officially take on the role of Principal, significantly enhancing the firm's capabilities. David Totaro's Impressive Background David brings vast...

Continue Reading
Hemlo Mining Corp. Unveils New Logo and Brand Identity

Updated Category News Views 169

Hemlo Mining Corp. Launches New Branding and Website New branding unveiled as part of the Company's exciting commencement of trading on TSXV The new logo reflects the Company's mission and values as a Canadian gold producer. Hemlo Mining Corp. (TSXV: HMMC) has officially launched its new logo, branding, and website. This significant development coincides with the first...

Continue Reading
Investigation Launched into GSK plc: What Investors Need to Know

Updated Category News Views 242

Understanding the Recent Investigation into GSK plc In a notable development, an investigation has been initiated regarding GSK plc. Investors who may have experienced losses related to GSK, or who have questions concerning their rights, are being urged to come forward and seek assistance. This action is being spearheaded by a prominent law firm focused on defending...

Continue Reading
Lead the Charge: Join PubMatic Investor Lawsuit Today

Updated Category News Views 137

Join the Lawsuit Against PubMatic, Inc. Investors have a significant opportunity to take a stand against PubMatic, Inc. This comes in light of the class action lawsuit initiated by The Schall Law Firm, aimed at holding the company accountable for alleged securities fraud. Those affected by smoking gun revelations regarding misleading statements can participate and...

Continue Reading